Pulse Biosciences/PLSE

$7.22

-0.55%
-
1D1W1MYTD1YMAX

About Pulse Biosciences

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Ticker

PLSE

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Kevin Danahy

Employees

56

Headquarters

Hayward, United States

PLSE Metrics

BasicAdvanced
$409.22M
Market cap
-
P/E ratio
-$0.89
EPS
1.72
Beta
-
Dividend rate
$409.22M
1.72317
$13.62
$3.78
172.19K
6.757
-61.61%
-200.47%
-67.89%
9.211
10.312
-100%
48.17%

What the Analysts think about PLSE

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 1 analyst.
30.75% downside
High $5.00
Low $5.00
$7.22
Current price
$5.00
Average price target

PLSE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-11.9M
13.33%
Profit margin
0%
-

PLSE Earnings Performance

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Q3 23
Actual
-
Expected
-$0.22
Surprise
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pulse Biosciences stock?

Pulse Biosciences (PLSE) has a market cap of $409.22M as of April 13, 2024.

What is the P/E ratio for Pulse Biosciences stock?

The price to earnings (P/E) ratio for Pulse Biosciences (PLSE) stock is 0 as of April 13, 2024.

Does Pulse Biosciences stock pay dividends?

No, Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Pulse Biosciences dividend payment date?

Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders.

What is the beta indicator for Pulse Biosciences?

Pulse Biosciences (PLSE) has a beta rating of 1.72. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Pulse Biosciences stock price target?

The target price for Pulse Biosciences (PLSE) stock is $5, which is 30.75% below the current price of $7.22. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pulse Biosciences stock

Buy or sell Pulse Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing